Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says
Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says Maia Anderson | Becker’s Hospital Review “An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S....
New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year
New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year Alex Brill | Washington, DC Today, Matrix Global Advisors (MGA) released a new report, “The Cost of Brand Drug Product Hopping,” commissioned by the Coalition for...- Health Care Workforce Shortages: An Updated Look
- New MGA Analysis of the Adalimumab Biosimilars Market in the United States
- MGA’s Alex Brill on CNBC’s Squawk Box Discussing the Recent Tax Policy Proposal
- Bipartisan Senate Bill Aims to Curb Drug Patent Abuse
- Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug
- New Report from MGA Examines the One-Year Cost Savings Lost Due to Patent Thickets
- New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit
- Narrow House GOP Victory Should Point Toward Policy Development Agenda
- Don’t Let Pandemic Fatigue Inhibit Pandemic Preparedness
- American Renewal: A Simpler, More Responsible, and Pro-Growth Tax System
